Recent research has identified two major features which influence the frequency and distribution Type I (insulin-dependent) diabetes mellitus in childhood. First, in the northern European countries a steady increase, about 3 % annually in incidence (and hence, disease risk), has been observed, during the last decades [1]. Second, on the global scale Europe has the highest risk of Type I diabetes that has been measured, ranging tenfold from Finland (highest) to South-eastern Europe (lowest) but with striking regional variations [1±3].
There are large variations in the incidence of Type I (insulin-dependent) diabetes mellitus within Europe, ranging from 3.2 cases per 100 000 person-years in the Republic of Macedonia to more than 40 new cases per 100 000 person-years in Finland. This variation could be caused by differences in the distribution of genetic susceptibility markers, by differences in the distribution of environmental disease determinants or by a combination of both. To assess how much genes contribute to this variation, we correlated the level of incidence of Type I diabetes with the prevalence in the general population of genetic susceptibility and protective markers encoded by the human leukocyte antigen (HLA)-DQ loci. Positive association was found for the combined group of genotypes associated with Type I diabetes risk (p < 0.001). The whole positive effect was, however, accounted for by the HLA-DQ2/ DQ8 (DQA1*0501-DQB1*0201/DQA1*0301-DQ-B1*0302) and HLA-DQ4/DQ8 (DQA1*0401-DQB1*0402/DQA1*0301-DQB1*0302) genotypes (p < 0.001 and p < 0.004, respectively). No correlation was found between incidence of Type I diabetes and population prevalence of genotypes not encoding for aspartate on position 57 on the HLA-DQ b chain. It was not possible to detect any negative correlation between Type I diabetes incidence and the prevalence of HLA-genotypes conferring protection against Type I diabetes in a population (HLA-DQA1*0102-DQB1*0602/X). The results suggest that a substantial part of the transnational variation in the incidence of childhood-onset Type I diabetes in Europe is explained by variations between populations in the distribution of particular DQ genotypes which confer a high risk of Type I diabetes in the general population. [Diabetologia (2001) 
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abetes with the prevalence of genetic susceptibility markers in the general population might throw light on this issue.
About 20 genomic regions have been identified which could contribute to Type I diabetes development [4±6]. The HLA region on the short arm of chromosome 6 is the most important, accounting for 42 % of the familiar clustering of Type I diabetes [4] . Type I diabetes is most strongly associated with HLA-DQA1 and DQB1 genes [7±10]. Several models have been put forward to explain this association. One study suggested that alleles encoding amino acids other than aspartic acid at DQb chain residue 57 (non-Asp57) are associated with Type I diabetes susceptibility [7] . Alleles encoding Asp57 appear to be associated with dominant protection [11] . However, other later studies indicate that the Type I diabetes association is more complex [12, 13] . Investigators have proposed that Type I diabetes is primarily associated with DQab heterodimers composed of a DQa chain having arginine at residue 52 in combination with a non-Asp57 DQb-chain [14, 15] . We have suggested that Type I diabetes could be primarily associated with five or six particular cis-encoded or transencoded DQab heterodimers [16, 17] . The DQab heterodimer encoded by DQA1*0102 and DQB1*0602 (found on a DR2 haplotype) seems to confer dominant protection [9, 17, 18] . Data from the 11th International Histocompatibility Workshop where 981 unrelated Type I diabetes patients and 2228 healthy control subjects were genomically HLA class II typed, revealed that the highest Type I diabetes risk among Caucasians is associated with six DQ genotypes [19] . Our ecological analysis tests associations between the HLA-DQ genotypes in a population with incidence rates of Type I diabetes.
Materials and methods
Type I diabetes incidence. New data on the incidence of Type I diabetes in childhood has been obtained from the EURODIAB studies [1, 2] . Our analysis uses data from the period 1989±1994 [1]. To increase statistical power, the incidence estimates from Finland and Sweden have been based on data covering their respective total populations [3] . The same sources also provided information on incidence in Russia. The incidence data which has formed the basis of our analyses is shown in Table 1 .
Genotype data. The HLA-DQA1 and -DQB1 genotypes were available for 11 736 healthy control subjects (genomic marker contributors) for 25 of the countries participating in the EU-RODIAB ACE network. The HLA class II genotyping was done at the local laboratories of the various network centres and was mainly carried out by polymerase chain reaction with subsequent hybridisation to sequence-specific oligonucleotide probes (PCR-SSOP) according to the protocols of the 11 th International HLA Workshop, while some centres used polymerase chain reactions with sequence-specific primers [20, 21] . a Standardized incidence rate is based on groups matched for (0±4, 5±9 and 10±14 years) of equal size Table 2 . HLA-DQ genotype data for control subjects, by population; absolute numbers (with genotype frequencies in brackets) Country The DQ genotypes were given a susceptibility score according to the formation of possible heterodimers, as suggested previously [9, 16] . We combined the six genotypes associated with Type I diabetes risk in Caucasians into one increased risk category classified as the genotype ªAllº in the calculations [19, 22] . Further separate analyses were performed for the category ªMaxº comprising the DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302 (DQ2/DQ8) genotype, as well as for the category ªStrongº comprising the ªMaxº (DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302) genotype together with the two homozygous combinations of its haplotypic components, DQA1*0301-DQB1*0302/ DQA1*0301-DQB1*0302 (DQ8/DQ8) and DQA1*0501-DQB1*0201 / DQA1*0501-DQB1*0201 (DQ2/DQ2). The remaining genotypes in the ªAllº class are denoted ªWeakº, and include DQA1*0101-DQB1*0501/DQA1*0301-DQB1*0302 (DQ5/DQ8), DQA1*0102-DQB1*0604/ DQA1*0301-DQB1*0302 (DQ6/DQ8) and DQA1*0401-DQB1*0402/DQA1*0301-DQB1*0302 (DQ4/DQ8). In addition, we analysed the distribution of DQB1 non-Asp57 homozygosity (named genotype ªASP-º) and of the Type I diabetes protective haplotype DQA1*0102-DQB1*0602 (named genotype ªDQ6/Xº).
The genotype data, for each country is shown in Table 2 . Even though genetic marker data exists from Ireland, this nation has not been included in the analysis because of the scarcity of epidemiological information, leaving Northern Ireland to represent the whole island.
Statistical analysis. An initial analysis was done by calculating Kendall's t (with adjustment for ties) [23] to examine the correlation between genotype frequencies and Type I diabetes incidence rates. This analysis weights each country equally and does not allow the relationship between genotype frequency and Type I diabetes incidence rate to be quantified. A straightforward regression of incidence rate on genotype frequency would not be correct because of the uncertainty in both variables [24, 25] . In our case the genotype frequencies and the Type I diabetes incidence rates are based on independent groups of individuals. This allowed us to develop a simple probability-based approach assuming binomial distribution of the HLA-DQ genotypes and standard Poisson distribution of the incident cases. This yields directly the joint probability function
with, for population i, X i = number of individuals with high risk genotypes n i = total number of individuals genotyped p i = population frequency of high risk genotype D i = number of new Type I diabetes patients observed S i = number of person-years observed l i = population Type I diabetes incidence.
We hypothesised that if a linear association exists between Type I diabetes incidence and genotype frequency, which could be reduced to proportionality with no association and no incidence variation as the extreme. This hypothesis was formally tested by the probability ratio criterion, with the full model (free variation, hypothesis H 0 ) as reference for H 1 , and H 1 as reference for the other models.
Results
The results of the correlation analysis are summarized in Table 3 . For the group of genotypes included in the class ªAllº there was evidence of a positive correlation with the population incidence of Type I diabetes (p < 0.001). However, when analysing subgroups of genotypes this evidence was established by two distinct genotypes, the ªMaxº genotype (DQA1*0501-DQB1*0201/DQA1*0301-DQB1 *0302) from the ªStrongº subgroup of ªAllº, and the ªDQ4/DQ8º genotype (DQA1*0401-DQB1*0402/ DQA1*0301-DQB1*0302) from the ªWeakº subgroup of ªAllº. The remaining subgroups of genotypes in ªAllº did not reach statistical significance in the correlation. Neither of the separate groups ªASP-º (DQB1-non Asp57 homozygozity) and ªDQ6/Xº (DQA1*0102-DQB1*0602 positive genotypes) showed a statistically significant correlation with the population Type I diabetes incidences. It is noteworthy that the protective genotype ªDQ6/Xº showed close to a significant positive correlation (p = 0.066). Plots of the correlation data are shown in Figure 1 . The group ªRestº, representing the complement of ªAllº, mirrors the correlation pattern of ªAllº.
In agreement with the initial correlation analysis, a linear model could only be fitted for the two genotypes ªMaxº (DQA1*0501-DQB1*0201/ and ªDQ4/DQ8º (DQA1*0401-DQB1*0402/DQA1*0301-DQB1* 0302). For both of these, the linear model could be further reduced to proportionality with regression coefficients (and SEM) for ªMaxº and ªDQ4/DQ8º at 700 (47) and 3500 (530), respectively and corresponding p values of 0.89 and 0.57, respectively. The fitted models are shown in Figure 2 . The probability based fit takes account of both the uncertainty in ordinate (diabetes incidence), as in ordinary regression, and the uncertainty in the abscissa (genotype frequency). This explains why the fit through the origin is marginally poorer than a fit with a freely varying intercept.
Both Finland and Sardinia represent outliners, with extremely high incidence rates and special characteristics of their population's genetic history and composition. However, excluding Finland and Sardinia from the analysis hardly changed the results (data not shown).
Discussion
An ecological analysis like ours could give rise to bias and limitations in interpretation [26] . Such biases are less relevant in the present context because we are dealing with genetic factors that are supposed to remain stable throughout life. It is, however, important to emphasise that our analysis describes variation between populations as a whole and cannot be immediately applied to determine individual susceptibility. A new statistical approach has been used to correct formally for variability in the sizes of the samples that provide incidence information as well as genetic marker information. This approach can be used to refine ecological analyses in general.
Our study has shown that the geographical variability of the population risk of Type I diabetes in Europe is partly attributable to the geographical variability in the population frequency of two distinct HLA-DQ susceptibility genotypes, namely DQ2/DQ8 (DQA1*0501-DQB1*0201/DQA1*0301-DQB1*0302) and DQ4/DQ8 (DQA1*0401-DQB1*0402/DQA1*0301-DQB1*0302). In line with this finding, the frequencies of these genotypes are highest among Type I diabetic patients in the northern part of Europe and lowest in southern Europe [19, 27] . The HLA associations for Type I diabetes show heterogeneity within the European Caucasian population. While different genotypic combinations with the DR4-DQA1*0301-DQB1*0302 haplotype are most important in northern Europe, different combinations with the DR3-DQA1*0501-DQB1*0201 haplotype are more important in southern Europe [19, 27] . The same is the case for the homozygous combinations of these two haplotypes because DR3-DQA1*0501-DQB1*0201 homozygosity plays the same role in southern Europe as DR4-DQA1*0301-DQB1*0302 does in northern Europe [19, 27] . Based on more recent knowledge of the different contribution of HLA-DQ genotypes within Europe, the correlation between incidence and genomic markers can only be determined when we know which genotypes confer Type I diabetes risk in a given population. Such data are also of enormous importance for Type I diabetes prediction and intervention studies.
We are well aware of the difficulties involved in defining a population on the principle of the nation state and therefore undertooked a separate analysis of Northern Ireland and Sardinia. The vast majority of the countries in our analysis are, however, homogenous. The changes in the political map of Europe over the past decade have brought a closer identification between state and nation. The Baltic states have separated from Russia, the Czechs from Slovaks. There are two states in our analysis to which this rule might not apply: these are two successor states of the former Yugoslavia, Croatia and the Republic of Macedonia.
In contrast to previous studies which attributed much of the geographic differences in Type I diabetes incidence to variations in the prevalence of the DQB1 non-Asp57 alleles in a population, we did not find that the prevalence of DQB1 Asp57 negative genotypes (referred to as ªASP-º) was correlated with Type I diabetes incidence (p = 0.20) [28, 29] . Our results confirm previous findings [30] presenting a more complex view of the genetics of Type I diabetes in a population. Our study has also not been able to demonstrate any protective effect of the HLA-DQB1*0602 allele at the population level. Conversely, its prevalence in the population was a close to significant positive correlation to Type I diabetes incidence (p = 0.066).
The presence of a strong positive correlation between population frequency of genetic susceptibility markers and population disease risk does not in itself exclude the importance of non-genetic factors (or genetic factors not accounted for in the analysis). All populations currently considered to be at a high and even extremely high Type I diabetes risk (eg. in Finland and the in other Nordic countries; Sardinia; UK), have had dramatic increases in the Type I diabetes incidence over the past decades, compared to a slower increase or no increase earlier [1, 31±33]. The increases cannot be explained by secular changes in the pool of susceptibility genes and imply that no correlation would have been detected between population frequency of susceptibility genotypes and the population risk of Type I diabetes if our analysis had been performed a few decades ago. These findings suggest that non-genetic causes interact with the genetic susceptibility factors in Type I diabetes and K. S. Rùnningen et al.: Incidence of Type I diabetes and HLA genotypes B 56 A B Fig. 2 A, B . Corresponding values of standardized incidence levels of Type I diabetes and population frequencies of the HLA genotypes DQ2/DQ8 (A) and DQ4/DQ8 (B), respectively. Lines indicate fit to proportionality model (Table 3) . Incidence rates are expressed per 100 000 person-years that such an interaction has been enhanced over the past decades in subjects carrying specific high-risk genotypes. If so, the distribution of HLA-genotypes in newly diagnosed Type I patients should change over time in populations who have changing incidences of Type I diabetes. The hypothesis could be supported by the rapid increase of Type I diabetes incidence in children in the age group 0±4 years, observed in particular in high-incidence populations of Finland and the UK [34±36]. This is because the prevalence of the risk genotypes is generally highest in the diabetic children with early disease onset [27] . Interaction between specific high-risk genotypes and early exposure to environmental risk factors (e. g. enteroviral infections) is believed to trigger beta-cell autoimmunity in susceptible individuals, because children converting to islet cell antibodies (ICA) positivity following enterovirus infection have been shown to carry high-risk HLA-DQB1 genotypes more often than children who remained ICA negative [37] .
Our study indicates avenues for further research to explain the complex causes of Type I diabetes. The currently defined high-risk populations are excellent for studies of gene-environment interactions in causing of Type I diabetes. However, comparative studies in low-risk populations could serve as an important reference. This type of research must necessarily incorporate genotyping of patients with Type I diabetes from the same populations.
